Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs

DR200300 _MiR_CPMRC

Several drugs are available for metastatic castration resistant prostate cancer such as chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide), in France. The oncologist has to choose between those two type of treatment, without any biological predictor of efficacy for his patient. It is always difficult to choose knowing that 30 to 50% of patients won't benefit from the treatment chosen. It shows why resistant mechanisms to treatment need to be elucidated. MicroRNA (miR) are short RNA, implicated in messenger ribonucleic acid (mRNA) regulation. Evidence is emerging that miR is implicated in prostate cancer response to treatment. It would be interesting to determine if a miR profile can predict treatment response to chemotherapy and/or to novel hormonal agents.

2021-06-23

2023-11-30

2023-11-30

Active (not recruiting)

33

Inclusion Criteria: * prostate adenocarcinoma * metastatic disease, proven (CT or bone scintigraphy or MRI or positron emission tomography(PET)-CT or X ray) * castration resistance, proven with biology or radiologic progression * affiliated to a french social security regimen Exclusion Criteria: * other cancer within five years * any judiciary protection measure

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Intervention: blood sample at inclusion. primary purpose: to better understand resistance mechanisms to prostate cancer treatment.', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 33, 'type': 'ACTUAL'}}

2023-11-29